Immunotherapy for anti-GQ1b IgG antibody-mediated disorders: role of electrophysiology in human trials

摘要

Sir, We read with interest the use of eculizumab as a protectionnagainst complement-mediated damage in a murine model of thenMiller Fisher syndrome (MFS). This monoclonal antibody not onlynresulted in protection against functional and morphological term-ninal motor neuropathy, but effectively prohibited respiratorynmuscle paralysis (Halstead et al., 2008). These important findingsnhave provided the basis for human trials in MFS, its relatedndisorders of Bickerstaff’s brainstem encephalitis (BBE) andnGuillain-Barre ´ syndrome (GBS), as well as neuropathies in whichnantibody-mediated complement activation may be pathophysiolo-ngically important (Compston, 2008; Lehmann and Hartung, 2008).